Literature DB >> 19877234

Dopamine transporter SPECT: how to remove subjectivity?

Christoph Scherfler1, Michael Nocker.   

Abstract

Clinical criteria enable accurate and reliable diagnosis of parkinsonian syndromes when cardinal clinical features are fully developed. Single photon emission computed tomography (SPECT) investigating the striatal dopamine transporter (DAT) status have been suggested to increase the diagnostic accuracy in uncertain parkinsonian syndromes such as isolated tremor symptoms not fulfilling essential tremor criteria, as well as drug-induced, vascular and psychogenetic parkinsonism. Several approaches for the analysis of the striatal DAT distribution have been tested for their ability to analyze and quantify SPECT images. Visual assessment of DAT binding and semiquantitative analysis using region of interests have been recommended by Nuclear Medicine Associations to be incorporated in the routine work-up of DAT-SPECT. Besides these observer dependent approaches, fully automated image-analysis techniques have been validated in the clinical setting. Their potential as tools to improve the diagnostic accuracy in patients presenting with parkinsonian features is reviewed here. Copyright 2009 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19877234     DOI: 10.1002/mds.22590

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

1.  Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Authors:  Elina Mäkinen; Juho Joutsa; Jarkko Johansson; Maija Mäki; Marko Seppänen; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2016-06-20       Impact factor: 3.575

2.  Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT.

Authors:  Michael Nocker; Klaus Seppi; Eveline Donnemiller; Irene Virgolini; Gregor K Wenning; Werner Poewe; Christoph Scherfler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-30       Impact factor: 9.236

3.  Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.

Authors:  I Navalpotro-Gomez; R Dacosta-Aguayo; F Molinet-Dronda; A Martin-Bastida; A Botas-Peñin; H Jimenez-Urbieta; M Delgado-Alvarado; B Gago; A Quiroga-Varela; Maria C Rodriguez-Oroz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-04       Impact factor: 9.236

4.  Comparison between Different Intensity Normalization Methods in 123I-Ioflupane Imaging for the Automatic Detection of Parkinsonism.

Authors:  A Brahim; J Ramírez; J M Górriz; L Khedher; D Salas-Gonzalez
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

5.  The feasibility of using CT-guided ROI for semiquantifying striatal dopamine transporter availability in a hybrid SPECT/CT system.

Authors:  Chien-Chin Hsu; Yen-Hsiang Chang; Wei-Che Lin; Shu-Wen Tang; Pei-Wen Wang; Yung-Cheng Huang; Nan-Tsing Chiu
Journal:  ScientificWorldJournal       Date:  2014-11-02

6.  Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy.

Authors:  Michael Nocker; Klaus Seppi; Sylvia Boesch; Eveline Donnemiller; Irene Virgolini; Gregor K Wenning; Werner Poewe; Christoph Scherfler
Journal:  Mov Disord Clin Pract       Date:  2016-11-02

7.  Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease.

Authors:  Luca Passamonti; Maria Salsone; Nicola Toschi; Antonio Cerasa; Marco Giannelli; Carmelina Chiriaco; Giuseppe Lucio Cascini; Francesco Fera; Aldo Quattrone
Journal:  Brain Behav       Date:  2013-03-22       Impact factor: 2.708

8.  Fully Automated Quantification of the Striatal Uptake Ratio of [(99m)Tc]-TRODAT with SPECT Imaging: Evaluation of the Diagnostic Performance in Parkinson's Disease and the Temporal Regression of Striatal Tracer Uptake.

Authors:  Yu-Hua Dean Fang; Shao-Chieh Chiu; Chin-Song Lu; Tzu-Chen Yen; Yi-Hsin Weng
Journal:  Biomed Res Int       Date:  2015-08-20       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.